Semaglutide UK: Regulatory Status, Price Variation and COA Checks

Is semaglutide legal to buy in the UK right now?

Yes, in specific licensed forms. Injectable Wegovy and injectable Ozempic both hold Medicines and Healthcare products Regulatory Agency (MHRA) marketing authorisation as prescription-only medicines (POM), meaning they can only be supplied against a prescription issued by a registered healthcare professional through a licensed pharmacy. A full breakdown of the authorisation history, including oral Wegovy, is covered in our separate guide to MHRA authorisations for semaglutide. What matters for this question is simpler: anything sold as semaglutide outside that licensed, prescription-based route — raw peptide, unbranded vials, drops, patches — does not hold a UK marketing authorisation and sits outside the Human Medicines Regulations 2012 (SI 2012/1916).

Why do UK results for "semaglutide UK" show such different prices?

Because the search term returns at least three distinct supply routes, and each one carries a different cost structure. Confusing them is the single biggest reason buyers misjudge what a "fair" UK price looks like.

A licensed injectable must be manufactured in a facility holding an MHRA Manufacturer's Licence, operate to Good Manufacturing Practice, and pass batch-release testing — identity, assay, sterility, endotoxin limits — signed off by a Qualified Person before sale. An unlicensed listing carries none of those fixed costs, which is the structural reason its headline price can sit well below a licensed product, independent of whatever the listing actually contains.

What did the 2023 counterfeit-pen alert reveal about UK supply?

In October 2023 the MHRA issued a national patient safety alert after fake Ozempic pens entered the UK supply chain containing undeclared insulin instead of semaglutide. Patients who used the counterfeit pens experienced unexpected hypoglycaemia, and a small number required hospital admission. The alert is one of the clearer pieces of evidence that packaging and branding alone cannot be trusted as proof of contents — the pens in question were visually convincing enough to pass through parts of the legitimate supply chain before detection. Current MHRA alerts and guidance are published at gov.uk/MHRA.

The practical lesson is not specific to counterfeit pens. It applies to any semaglutide-labelled product reaching a UK buyer outside a verified pharmacy chain: a label, a logo, or a seller's own purity claim is marketing, not evidence. The only objective evidence of what a specific batch contains is an independent laboratory's Certificate of Analysis (COA) for that exact lot.

What should a genuine Certificate of Analysis for semaglutide show?

A COA that actually proves anything is issued per batch, by a laboratory independent of the seller, and references the precise lot number of the material in question — not a generic specification sheet reused across batches. Three elements distinguish a real COA from a marketing document:

• Purity by HPLC. High-performance liquid chromatography purity is reported as a percentage. Reputable reference-grade material is typically reported at 98% or above; results meaningfully below that, or reported without a chromatogram, warrant scrutiny.
• Identity by mass spectrometry. HPLC purity alone does not confirm the molecule is semaglutide rather than a similarly sized impurity or a different peptide entirely — mass spec confirms the molecular identity independently.
• Lot-specific traceability. The COA must name the exact batch it tested, with a date, so it can be matched to the specific vial or sample in hand rather than to an unrelated reference batch.

None of this converts an unlicensed product into a licensed medicine, and a strong COA on research-use material does not establish suitability for human administration — that determination sits with the MHRA's marketing authorisation framework described above. What a proper COA does is remove ambiguity about what a specific batch of material actually is, which is the minimum standard any independent testing claim should meet.

Does a lower price automatically mean lower quality?

Not necessarily, but it removes the specific assurances that justify a higher price elsewhere. Price alone is not a quality signal in either direction: a high price does not guarantee a batch is what it claims to be, and a low price does not guarantee the opposite. The only way to separate the two is documentation — a licensed product's MHRA authorisation and pharmacy dispensing record, or an unlicensed product's independent, lot-matched COA. Absent either, price is simply uninformative.

Summary

"Semaglutide UK" is not a single product or a single price — it spans an NHS pathway, private prescribing, and an unlicensed online market, each governed by different rules and different quality controls. Injectable Wegovy and Ozempic hold MHRA marketing authorisation as prescription-only medicines; everything outside that licensed route sits outside the Human Medicines Regulations 2012. The 2023 counterfeit-pen alert is a reminder that packaging cannot substitute for verification, and that an independent, lot-specific Certificate of Analysis — HPLC purity, mass-spec identity, matched batch number — is the only objective way to know what a given sample actually is.